Skip to main content
Equibles
AYTU logo

AYTU · Aytu Biopharma, Inc

Track AYTU — free

Use AYTU with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AYTU

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.38 +0.08 (+3.48%) At close · Aug 14
Market Cap
$25.55M
Shares
10.73M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.38 Open$2.33 Day$2.33–2.41 52W close$1.71–2.90 Avg vol 30d28K Short int326K · 3.0% float · 12.5d Short vol17% Last earningsMay 13, 2026 DataJan 2023–Aug 2026 Filing10-Q · May 13

Raw chart and full-history price indicators begin at the captured split on Jan 6, 2023; bars on opposite sides are not compared.

Up next

FQ1-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Bullish Fundamentals Excellent Quant / Vol High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +0%
      above
      Price vs 50-day avg +8%
      above
      RSI (14) 61
      neutral
      MACD trend Positive
      52-week position 56%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Neutral
      1-month return +11%
      trailing
      6-month return +5%
      trailing
      YTD return −8%
      this year
      Relative strength −9%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +3% holders QoQ · +3 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.04% of float · ▼ -6.0% MoM · 12.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      38 holders — near 3-yr high, broad support
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +277%
      Y/Y
      Gross margin 166%
      contracting
      EPS growth +93%
      Y/Y
      Free cash flow $-2.2M
      Balance sheet $15.8M
      net cash
      Quant / Vol
      risk profile
      High
      Volatility 53%
      annualized · 1-yr
      Max drawdown −32%
      past year
      ATR 3.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Dec 31, 2024
      Future cost savings expected annually · annually going forward at least $2M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +0% Bullish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      61 Neutral
      MACD trend
      Positive Bullish
      52-week position
      56% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +3% holders QoQ · +3 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.04% of float · ▼ -6.0% MoM · 12.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      38 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $2 Now $2 · 56% Range high $3
      vs 200-day avg +0% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      EXXUA net revenue $2.4M Q3 fiscal 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AYTU
      Aytu Biopharma, Inc
      this stock
      		$25.55M -8.5% +277.5% — 3.0%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $56.30B +13.1% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.49B +2.4% — — 0.0%
      TEVA
      Teva Pharmaceutical Industries Ltd
      		 $42.85B +17.8% +4.3% 60.3 2.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      38
      % held
      73.7%
      Net QoQ
      +4.0M sh
      Top holder
      Stonepine Capital Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      15
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      326.2K
      Days to cover
      12.5d
      Change
      -20.8K sh
      View
      Short Volume
      Short vol %
      17%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.1K
      Value
      $4.7K
      As of
      Jul 13, 2026
      View
      Off-Exchange
      Off-exchange %
      62.6%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $66.4M
      Net income (FY)
      $-13.6M
      EPS diluted
      $-5.11
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 25, 2026
      This year
      7
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 13, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jan 6, 2023; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      AYTU +0.9% +10.7% +4.9% +6.7% -8.5%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +0.5% +6.3% -8.9% +2.8% -22.3%
      Key facts CIK 1385818 CUSIP 054754858 13F (30d) 37 filings 37 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)